NCT02624388 · OUTCOME

Serum Marker Levels of Inflammation Erythrocyte Sedimentation Rate (ESR; mm/hr) During Cycles of Chemotherapy

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) · Source last updated 2024-05-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: mm/hr
Interval / dispersion: Standard Deviation
Time frame: Once before treatment starts and then four more times while the study drug is being taken, an 8 - 16 week period if there are no chemotherapy delays

Groups in this outcome

Arm A: Genistein Followed by Placebo

Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4 Genistein: Estrogen-like compound (isoflavone) derived from soybeans Placebo: Pill that contains no medicine

Arm B: Placebo Followed by Genistein

Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4 Genistein: Estrogen-like compound (isoflavone) derived from soybeans Placebo: Pill that contains no medicine

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm A: Genistein Followed by Placebo	2
Arm B: Placebo Followed by Genistein	2

Reported measurements

ESR, Genistein cycles

Values in mm/hr · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Arm A: Genistein Followed by Placebo	14.67	4.93	Not reported	Not reported	Not reported
Arm B: Placebo Followed by Genistein	3.25	1.5	Not reported	Not reported	Not reported

ESR, Placebo cycles

Values in mm/hr · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Arm A: Genistein Followed by Placebo	20.00	5.29	Not reported	Not reported	Not reported
Arm B: Placebo Followed by Genistein	2.50	0.58	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
4.93
value
14.67
group Id
OG001
spread
1.5
value
3.25
title
ESR, Genistein cycles
categories
measurements
group Id
OG000
spread
5.29
value
20.00
group Id
OG001
spread
0.58
value
2.50
title
ESR, Placebo cycles

denoms

counts
group Id
OG000
value
2
group Id
OG001
value
2
units
Participants

dispersion Type

Standard Deviation

groups

description
Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4 Genistein: Estrogen-like compound (isoflavone) derived from soybeans Placebo: Pill that contains no medicine
id
OG000
title
Arm A: Genistein Followed by Placebo
description
Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4 Genistein: Estrogen-like compound (isoflavone) derived from soybeans Placebo: Pill that contains no medicine
id
OG001
title
Arm B: Placebo Followed by Genistein

param Type

MEAN

reporting Status

POSTED

time Frame

Once before treatment starts and then four more times while the study drug is being taken, an 8 - 16 week period if there are no chemotherapy delays

title

Serum Marker Levels of Inflammation Erythrocyte Sedimentation Rate (ESR; mm/hr) During Cycles of Chemotherapy

type

SECONDARY

unit Of Measure

mm/hr

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice